Diagnostic Substances More
- 51-200 Employees
- Based in Vista, California
Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention. Exagen has developed and is commercializing a portfolio of innovative testing products under its AVISE® brand. Several of these products are based on their proprietary Cell-Bound…More Complement Activation Products (CB-CAPs), technology. CB-CAPs assess the activation of the complement system, a biological pathway implicated in systemic lupus erythematosus (SLE). Exagen’s goal is to enable rheumatologists to improve care for patients through the differential diagnosis, prognosis and monitoring of complex autoimmune and autoimmune-related diseases, including SLE and rheumatoid arthritis, or RA. Exagen’s model of integrating testing products and therapeutics positions Exagen to offer targeted solutions to rheumatologists and, ultimately, better serve patients.
Most Recent Responsibility Report
2022 ESG Report
Archived Responsibility Reports
Our service enables potential investors to review the most recent and archived Exagen Inc. Sustainability Report, Exagen Inc. Corporate Social Responsibility Report, Exagen Inc. CSR Report, Exagen Inc. Corporate Responsibility, Exagen Inc. CR Report, Exagen Inc. Citizenship Report, Exagen Inc. ESG Report, and Exagen Inc. Environmental Report online.